Cerebrolysin vs PACAP-38 — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Cerebrolysin is a heterogeneous neuropeptide complex derived from enzymatic hydrolysis of purified porcine brain cortex proteins. Approximately 25% of the preparation consists of low molecular weight peptides (under 10 kDa) that cross the blood-brain barrier, with the remainder b...
Calculate Cerebrolysin dose →Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP-38) is a 38-amino-acid member of the VIP/secretin/glucagon superfamily, first isolated from ovine hypothalamus in 1989 by Miyata and colleagues based on its ability to stimulate adenylate cyclase in pituitary cells. PACAP-...
Calculate PACAP-38 dose →| Parameter | Cerebrolysin | PACAP-38 |
|---|---|---|
| Category | Neuropeptides & Cognition | Neuropeptides & Cognition |
| Research | Extensively Studied (Europe/Asia; Not FDA Approved) | Extensively Studied (Preclinical) |
| Half-Life | Short (hours for individual peptides) | 2-5 min (plasma); longer in CNS |
| Typical Dose | 5-30 mL/day IV (pharmaceutical); research 5-10 mL | 300-600 mcg intranasal; 100-300 mcg SC |
| Frequency | Daily for 10-21 day courses | As needed or daily for neuroprotection protocols |
| Route | Intravenous, Intramuscular | Intranasal, Subcutaneous, IV |
| FDA Status | Not Approved (US) | Not Approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.